Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Conditions:   Acute Myeloid Leukemia With KMT2A Rearrangement;   Acute Myeloid Leukemia With NPM1 Mutation Interventions:   Procedure: Biospecimen Collection;   Procedure: Bone Marrow Aspiration;   Procedure: Bone Marrow Biopsy;   Drug: Cytarabine;   Drug: Daunorubicin;   Procedure: Multigated Acquisition Scan;   Drug: Revumenib;   Procedure: Transthoracic Echocardiography Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials